AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12011706 — intervention group
Group type: COMPARATOR
Intervention: No pneumatic compression (control)
Number of subjects: 50
Study 10214571 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON‐L
Number of subjects: 298
Study 10214571 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 298
Study 10214571 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 298
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: Radical esophagectomy with lower mediastinal and abdominal lymphadenectomy (Group A, n = 39)
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: Radical esophagectomy with incomplete 2-field dissection (Group B, n = 94)
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: Radical esophagectomy with extended cervicothoraco-abdominal lymph node dissection (3-field dissection) (Group C)
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: Radical esophagectomy with 3-field dissection (Group D)
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: Complete 2-field dissection
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: 3-field dissection
Number of subjects: 403
Study 7793992 — intervention group
Group type: COMPARATOR
Intervention: 2-field or 3-field dissection in cases with 7 or more positive lymph node metastases
Number of subjects: 403
Study 1977089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocte
Number of subjects: 230
Study 1977089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.d.
Number of subjects: 230
Study 1977089 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 230
Study 1977089 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 230
Study 341950 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 60 mg daily
Number of subjects: 54
Study 341950 — intervention group
Group type: COMPARATOR
Intervention: imipramine 150 mg daily
Number of subjects: 54
Study 341950 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 54
Study 341950 — intervention group
Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 54
Study 31886693 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with educational information about newborn genomic sequencing and a values clarification exercise
Number of subjects: 1000
Study 31886693 — intervention group
Group type: COMPARATOR
Intervention: Decision aid with educational information about newborn genomic sequencing
Number of subjects: 1000
Study 31527377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifiprost® + Serenoa Repens 320 mg
Number of subjects: 120
Study 31527377 — intervention group
Group type: COMPARATOR
Intervention: Serenoa Repens 320 mg alone
Number of subjects: 120
Study 27788498 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide long-acting release (LAR) maintenance treatment
Number of subjects: 40
Study 27788498 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in high proliferation NET group
Number of subjects: 40
Study 27788498 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP) followed by octreotide LAR maintenance treatment in poorly differentiated NEC (PDNEC) group
Number of subjects: 40
Study 26718296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem containing toothpaste
Number of subjects: 30
Study 23910702 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist intervention
Number of subjects: 48
Study 22194781 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality and Outcomes Framework (QOF) pay-for-performance programme
Number of subjects: 0
Study 19076535 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 399
Study 19076535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 16737936 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of oral valganciclovir
Number of subjects: 22
Study 16737936 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg of intravenous ganciclovir
Number of subjects: 22
Study 15218993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium-AM
Number of subjects: 95
Study 15218993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium-PM
Number of subjects: 95
Study 15218993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium pooled
Number of subjects: 95
Study 15218993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 10926890 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for interpreting consecutive measurements of cancer markers (CA 15.3, CEA, TPA)
Number of subjects: 0
Study 10926890 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for monitoring tumor marker measurements
Number of subjects: 0
Study 9495661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =90 mmHg
Number of subjects: 922
Study 9495661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =85 mmHg
Number of subjects: 922
Study 9495661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP levels < or =80 mmHg
Number of subjects: 922
Study 9495661 — intervention group
Group type: EXPERIMENTAL
Intervention: All target groups
Number of subjects: 922
Study 8455128 — intervention group
Group type: EXPERIMENTAL
Intervention: Worth four‐dot (W4D) test
Number of subjects: 107
Study 8455128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized four‐dot (P4D) test
Number of subjects: 107
Study 3527086 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (1 mg/kg for the first month, 2 mg/kg for the second month)
Number of subjects: 8
Study 3527086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28277811 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-motor intervention
Number of subjects: 0
Study 28277811 — intervention group
Group type: COMPARATOR
Intervention: Stochastic vibration plus perceptual-motor intervention
Number of subjects: 0
Study 25920707 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 284
Study 25920707 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 284
Study 25424809 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine with prophylactic paracetamol
Number of subjects: 0
Study 25424809 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine without prophylactic paracetamol
Number of subjects: 0
Study 25424809 — intervention group
Group type: COMPARATOR
Intervention: MenC vaccine
Number of subjects: 0
Study 25424809 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with 4CMenB
Number of subjects: 0
Study 25424809 — intervention group
Group type: COMPARATOR
Intervention: Routine infant vaccines (DTaP-HBV-IPV/Hib and PCV7) with MenC
Number of subjects: 0
Study 23706291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve lateralization (NL)
Number of subjects: 21
Study 23706291 — intervention group
Group type: COMPARATOR
Intervention: Nerve transposition (NT)
Number of subjects: 21
Study 19874395 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63
Study 19874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 63
Study 19874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil and Memantine
Number of subjects: 63
Study 18992601 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16118355 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 31
Study 16118355 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulative treatment
Number of subjects: 31
Study 12114877 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep injection of radiotracer (group B)
Number of subjects: 400
Study 12114877 — intervention group
Group type: COMPARATOR
Intervention: Superficial injection of radiotracer (group A)
Number of subjects: 400
Study 12114877 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep injection of radiotracer (in outer quadrant patients)
Number of subjects: 400
Study 12114877 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided IMC biopsy
Number of subjects: 400
Study 12114877 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of axillary plus IMC nodes
Number of subjects: 400
Study 9923808 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60
Study 9923808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study 9923808 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 7757308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.)
Number of subjects: 24
Study 7757308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg t.i.d.) with Propranolol (40 mg t.i.d.)
Number of subjects: 24
Study 7757308 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 24
Study 11527140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 129
Study 11527140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 129
Study 11527140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/day
Number of subjects: 129
Study 11527140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol 10 mg/day
Number of subjects: 129
Study 11527140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1-month run-in period)
Number of subjects: 129
Study 6271381 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVP-AD regimen (cyclophosphamide, VP-16, vincristine, cisplatin alternating with doxorubicin and DTIC)
Number of subjects: 66
Study 6271381 — intervention group
Group type: EXPERIMENTAL
Intervention: AVVP-CD regimen (doxorubicin, VP-16, vincristine, and cisplatin alternating with cyclophosphamide and DTIC)
Number of subjects: 66
Study 6271381 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of both regimens
Number of subjects: 66
Study 6271381 — intervention group
Group type: COMPARATOR
Intervention: Prognostic variables
Number of subjects: 66
Study 6271381 — intervention group
Group type: COMPARATOR
Intervention: CNS metastases
Number of subjects: 66
Study 6271381 — intervention group
Group type: COMPARATOR
Intervention: Sites of disease progression
Number of subjects: 66
Study 30070034 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-needle mesotherapy with 20% L-ascorbic acid serum
Number of subjects: 17
Study 30070034 — intervention group
Group type: COMPARATOR
Intervention: No-needle mesotherapy with 20% L-ascorbic acid serum
Number of subjects: 17
Study 31411375 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nurse-led lifestyle-modification intervention
Number of subjects: 61
Study 31411375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery arm (direct distribution of an oral HIVST from the peer educator)
Number of subjects: 965
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupon arm (a coupon for collection of an oral HIVST from a health clinic/pharmacy)
Number of subjects: 965
Study 29161260 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care arm (standard HIV testing)
Number of subjects: 965
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery arm
Number of subjects: 965
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupon arm
Number of subjects: 965
Study 29161260 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care arm
Number of subjects: 965
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care in HIVST arms
Number of subjects: 965
Study 29161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 965
Study 25627884 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakult® (Treatment A)
Number of subjects: 10
Study 25627884 — intervention group
Group type: EXPERIMENTAL
Intervention: Batavito® (Treatment B)
Number of subjects: 10
Study 25627884 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakult® (Treatment C)
Number of subjects: 10
Study 25627884 — intervention group
Group type: EXPERIMENTAL
Intervention: Batavito® (Treatment D)
Number of subjects: 10
Study 22746245 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose lithium treatment (300 μg, administered once daily for 15 months)
Number of subjects: 0
Study 22746245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be without lithium treatment)
Number of subjects: 0
Study 21684478 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg for 8 months
Number of subjects: 50
Study 21684478 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 50
Study 18689695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (waist circumference, hypertension, smoking, family history of diabetes)
Number of subjects: 3817
Study 18689695 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation including fasting glucose, waist circumference, smoking, and gamma-glutamyltransferase for men; fasting glucose, BMI, triglycerides, and family history of diabetes for women.
Number of subjects: 3817
Study 18689695 — intervention group
Group type: EXPERIMENTAL
Intervention: TCF7L2 and IL6 deleterious alleles
Number of subjects: 3817
Study 16468063 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm stroke propelling efficiency (etaP)
Number of subjects: 63
Study 16468063 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance covered per stroke (Ds)
Number of subjects: 63
Study 16468063 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-to-hand distance (l)
Number of subjects: 63
Study 16468063 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy cost of swimming (C)
Number of subjects: 63
Study 12846597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 24mg
Number of subjects: 0
Study 12846597 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50mg
Number of subjects: 0
Study 12846597 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.1 mg/kg (IV infusion)
Number of subjects: 0
Study 12846597 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 60mg
Number of subjects: 0
Study 12846597 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran (active form of ximelagatran)
Number of subjects: 0
Study 11527638 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788
Study 11527638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study 9307902 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐directional MR velocity mapping
Number of subjects: 28
Study 8364132 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day ZnSO4
Number of subjects: 27
Study 8364132 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day ZnSO4
Number of subjects: 27
Study 8364132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3538460 — intervention group
Group type: EXPERIMENTAL
Intervention: misonidazole (1 g/m2 body surface)
Number of subjects: 91
Study 3538460 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 29728296 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated cartoon
Number of subjects: 150
Study 29728296 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Number of subjects: 150
Study 29728296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Buzzy® and animated cartoon
Number of subjects: 150
Study 29728296 — intervention group
Group type: COMPARATOR
Intervention: No method (control group)
Number of subjects: 150
Study 25370571 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (cognitive behavioural therapy combined with counselling techniques)
Number of subjects: 54
Study 25370571 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 25278107 — intervention group
Group type: COMPARATOR
Intervention: Social exclusion (via writing prime)
Number of subjects: 0
Study 25278107 — intervention group
Group type: COMPARATOR
Intervention: Social exclusion (via Cyberball)
Number of subjects: 0
Study 25278107 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease threat prime
Number of subjects: 0
Study 25278107 — intervention group
Group type: COMPARATOR
Intervention: General negative affective state prime
Number of subjects: 0
Study 21705786 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants (BMI categorized as obese)
Number of subjects: 3207
Study 21705786 — intervention group
Group type: COMPARATOR
Intervention: Normal weight participants (BMI categorized as normal weight)
Number of subjects: 3207
Study 21705786 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men (BMI categorized as obese)
Number of subjects: 3207
Study 21705786 — intervention group
Group type: COMPARATOR
Intervention: Normal weight men (BMI categorized as normal weight)
Number of subjects: 3207
Study 21705786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis for obesity effects
Number of subjects: 3207
Study 20175096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0
Study 18945365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hausa version of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM)
Number of subjects: 67
Study 18945365 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale for pain intensity
Number of subjects: 67
Study 16148467 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation + Automatic Tube Compensation (PAV+ATC)
Number of subjects: 12
Study 16148467 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 12
Study 16148467 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12
Study 14726838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fondaparinux
Number of subjects: 0
Study 14726838 — intervention group
Group type: COMPARATOR
Intervention: Low‐molecular‐weight heparin
Number of subjects: 0
Study 10658543 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ppm toluene for 3 hours
Number of subjects: 0
Study 10658543 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (filtered air) for 3 hours
Number of subjects: 0
Study 8911981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (5 mg)
Number of subjects: 0
Study 8911981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 0
Study 8911981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2476641 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activating factor (PAF) supplementation (0.186, 0.93, or 1.49 mumol/1)
Number of subjects: 351
Study 2476641 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mumol/1 PAF)
Number of subjects: 351
Study 2476641 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activating factor (PAF) supplementation
Number of subjects: 351
Study 827759 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline (Elavil)
Number of subjects: 20
Study 827759 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (Ritalin)
Number of subjects: 20
Study 827759 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31178508 — intervention group
Group type: EXPERIMENTAL
Intervention: Kikyo-to (KKT) 2.5 g
Number of subjects: 70
Study 31178508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31178508 — intervention group
Group type: EXPERIMENTAL
Intervention: Kikyo-to (KKT)
Number of subjects: 70
Study 29217521 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Balloon (LB)
Number of subjects: 134
Study 29217521 — intervention group
Group type: COMPARATOR
Intervention: Wide-Area Circumferential Radiofrequency Ablation (RF)
Number of subjects: 134
Study 25656334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (n = 27)
Number of subjects: 54
Study 25656334 — intervention group
Group type: COMPARATOR
Intervention: Standard information and support (Control group, n = 27)
Number of subjects: 54
Study 23443723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg
Number of subjects: 9
Study 23443723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21485567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavicular hook plate fixation (Group A)
Number of subjects: 65
Study 21485567 — intervention group
Group type: EXPERIMENTAL
Intervention: Coracoid transplantation (Group B)
Number of subjects: 65
Study 21485567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavicular hook plate fixation combined with modified dynamic muscle transfer (Group C)
Number of subjects: 65
Study 19688837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.3 mg/kg body weight, maximum 10 mg)
Number of subjects: 50
Study 19688837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22316568 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms (measured by PANSS negative factor)
Number of subjects: 1447
Study 22316568 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms (improvement)
Number of subjects: 1447
Study 22316568 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes (measured by Calgary Depression Rating Scale and select items from Heinrich's and Lehman's Quality of Life Scales)
Number of subjects: 1447
Study 15885227 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic blood
Number of subjects: 42
Study 15885227 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic crystalloid
Number of subjects: 42
Study 15885227 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic blood
Number of subjects: 42
Study 15885227 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic groups
Number of subjects: 42